TFA Therapeutics (RAJAF) EBITDA Margin (2020 - 2023)
TFA Therapeutics (RAJAF) posted EBITDA Margin of 38.18% for Q4 2023, up 109.83% on a QoQ basis from 388.47% in Q4 2022, and up 42665.0% year-over-year from N/an in Q4 2022.
Powered by 
Analysis
TFA Therapeutics (RAJAF) EBITDA Margin (2020 - 2023) Analysis & Trends
TFA Therapeutics has reported EBITDA Margin for 3 years, with the latest figure at 38.18% in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Colgate Palmolive | 70.71 Bn | 69.34 Bn | 3.30 Bn | 18.95% |
| 2 | Kenvue | 34.23 Bn | 33.12 Bn | 2.30 Bn | 17.67% |
| 3 | Kimberly Clark | 32.91 Bn | 31.95 Bn | 1.60 Bn | 15.11% |
| 4 | Bath & Body Works | 3.73 Bn | 2.93 Bn | 692.00 Mn | 14.27% |
| 5 | Prestige Consumer Healthcare | 2.35 Bn | 2.28 Bn | - | - |
| 6 | Perrigo | 1.98 Bn | 1.58 Bn | 313.90 Mn | 2.30% |
| 7 | Herbalife | 1.29 Bn | 916.98 Mn | 1.03 Bn | 9.67% |
| 8 | Edgewell Personal Care | 1.24 Bn | 840.69 Mn | 242.50 Mn | 4.39% |
| 9 | TFA Therapeutics | 1.02 Bn | 1.02 Bn | - | - |
| 10 | Honest Company | 600.74 Mn | 494.84 Mn | 40.36 Mn | 11.50% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 38.18% |
| Dec 31, 2022 | -388.47% |
| Dec 31, 2020 | 6.56% |